This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

30/100

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly. Current international guidelines for the clinical diagnosis of AD consider the diagnosis to be both clinical and biological. It requires a specific clinical phenotype and a confirmed biological origin based on biomarkers of amyloid and tau pathology. In Russia, only a few research centers perform laboratory diagnosis of AD using cerebrospinal fluid (CSF) biomarkers. Better access to laboratory diagnosis of AD and wider use of CSF biomarkers in clinical practice will help to assess the true prevalence of AD in the Russian population and to select patients for targeted pathogenic therapies based on the use of monoclonal antibodies against abnormal brain proteins, which have been actively developed in recent years. This review summarizes information on the main CSF biomarkers of AD and their diagnostic and prognostic value.

What this study adds

Evidence grade: Low

This review summarizes cerebrospinal fluid biomarkers of amyloid and tau pathology used in the clinical and biological diagnosis of Alzheimer disease. It notes that better access to such testing in Russia would help assess the true prevalence of AD and select patients for targeted therapies using monoclonal antibodies against abnormal brain proteins.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Nevzorova, K. V., Shpilyukova, Y. A., Шабалина, А. А., Fedotova, E. Y., & Illarioshkin, S. N. (2025). Cerebrospinal Fluid Biomarkers of Alzheimer Disease. Annals of Clinical and Experimental Neurology. https://doi.org/10.17816/acen.1185

Vancouver

Nevzorova KV, Shpilyukova YA, Шабалина АА, Fedotova EY, Illarioshkin SN. Cerebrospinal Fluid Biomarkers of Alzheimer Disease. Annals of Clinical and Experimental Neurology. 2025. doi:10.17816/acen.1185.

BibTeX

@article{nevzorova2025-d9bca389,
  author  = {Nevzorova, Kseniya V. and Shpilyukova, Yu. A. and Шабалина, Алла Анатольевна and Fedotova, E. Yu. and Illarioshkin, Sergey Nikolaevich},
  title   = {{Cerebrospinal Fluid Biomarkers of Alzheimer Disease}},
  journal = {Annals of Clinical and Experimental Neurology},
  year    = {2025},
  doi     = {10.17816/acen.1185},
  url     = {https://doi.org/10.17816/acen.1185}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Current international guidelines for the clinical diagnosis of AD consider the diagnosis to be both clinical and biological.
It requires a specific clinical phenotype and a confirmed biological origin based on biomarkers of amyloid and tau pathology.
In Russia, only a few research centers perform laboratory diagnosis of AD using cerebrospinal fluid (CSF) biomarkers.
Better access to laboratory diagnosis of AD and wider use of CSF biomarkers in clinical practice will help to assess the true prevalence of AD in the Russian population and to select patients for targeted pathogenic therapies based on the use of monoclonal antibodies against abnormal brain proteins, which have been actively developed in recent years.
This review summarizes information on the main CSF biomarkers of AD and their diagnostic and prognostic value.

Why it matters

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 30/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 29 of the 97 points we could judge it on, which is 30 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Annals of Clinical and Experimental Neurology)
Journal's citation record	0 / 4	Annals of Clinical and Experimental Neurology: journal h-index 10 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Sergey Nikolaevich Illarioshkin: h-index 31 (OpenAlex, whole career)
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multicenter collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	29 / 97	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 97 points we could judge it on is 30 out of 100.
Total	30 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 27.

Related studies in Treatments from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →